Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1 Windsor, United Kingdom/Valby, Denmark, 27 March 2024 – Otsuka Pharmaceutical ...

If approved, aripiprazole 2-month ready-to-use (RTU), long-acting injectable (LAI) would be the first 2-month, LAI antipsychotic indicated for both treatment of schizophrenia and the maintenance ...

Schizophrenia, a neuropsychiatric disorder affecting more than 1% of the world's population, is a devastating and costly disease. As of 1991, it was estimated that costs associated with schizophrenia ...

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...

If you have schizophrenia, your doctor may want you to take aripiprazole. That’s a prescription drug sold under the brand name Abilify. Aripiprazole is an atypical or second-generation antipsychotic ...

Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Control of ...

Aripiprazole enhances the entrainment to external light-dark cycles by weakening the synchronization between neurons in the central circadian clock, thereby improving the symptoms of circadian rhythm ...

Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is used for relief of acute psychotic episodes and prevention of subsequent relapse, is essential for ...